C5 and myasthenia gravis: Eculizumab, an anti‐C5 monoclonal antibody (mAb), was a landmark in this work, approved by the US Food and Drug Administration (FDA) in 2007 for use in PNH,9, 10, 11 years later for aHUS12 and recently for myasthenia gravis (MG) (news.alexionpharma.com/press‐release/product‐news/fda‐approves‐soliris‐eculizumab‐treatment‐patients‐generalized‐myasthenia).